BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne's first product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother's blood. BillionToOne was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D. For more information, visit www.billiontoone.com.
BillionToOne announces groundbreaking new COVID-19 test to unlock 1...
Unique Testing Protocol from Precision Diagnostics Company Unlocks 1 Million Tests Per Day MENLO PARK, CA (April 7, 2020) - The precision... read more
07.04.2020 • By Billiontoone, Inc